In the first group, the DIGAMI 1 trial studied the effects of intensive in-hospital insulin treatment (insulin-glucose infusion for at least 24 h followed by subcutaneous multiple dose insulin regimen) versus the conventional treatment in 620 patients with ACS and established diabetes and/or admission glucose of >200 mg/dL (11 mmol/L) [81]. The gene discussed is INS; the disease is diabetes mellitus.